Segment disclosures

Company overview

Verastem, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

3 dimension combinations 15 retained observations 10 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Product · Research Developing And Commercialization Drugs Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-09-3067761000 USD20261105Open filing evidence
2026-01-01 – 2026-06-3043749000 USD20260806Open filing evidence
2025-01-01 – 2025-12-3130914000 USD20260304Open filing evidence
2025-07-01 – 2025-09-3011242000 USD20251104Open filing evidence
2025-01-01 – 2025-09-3013379000 USD20261105Open filing evidence
2025-04-01 – 2025-06-302137000 USD20250807Open filing evidence
2025-01-01 – 2025-06-302137000 USD20260806Open filing evidence

Copiktra License And Related Assets · Research Developing And Commercialization Drugs Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vstm:CopiktraLicenseAndRelatedAssetsMember;us-gaap:StatementBusinessSegmentsAxis=vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-09-3015000000 USD20261105Open filing evidence
2026-01-01 – 2026-06-3015000000 USD20260806Open filing evidence
2024-01-01 – 2024-12-3110000000 USD20260304Open filing evidence
2024-01-01 – 2024-09-3010000000 USD20251104Open filing evidence
2024-04-01 – 2024-06-3010000000 USD20250807Open filing evidence

Research Developing And Commercialization Drugs Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-03-3118671000 USD20260507Open filing evidence
2024-01-01 – 2024-12-3110000000 USD20250320Open filing evidence
2022-01-01 – 2022-12-312596000 USD20250320Open filing evidence